Abstract:A panel of experts recently completed updating the European Guidelines for the use of Ultrasound Contrast Agents. It is due to be published in early 2008 and updates and extends the 2004 Guidelines, which covered only the liver. The new liver section, which includes the use of USCM in interstitial ablation, incorporates the recent Barcelona guidelines for management of focal lesions discovered during ultrasound surveillance in cirrhotic patients. Though focussed on SonoVue, it forms a useful framework for a general discussion of this topic. It also covers clinically established uses in the kidneys and pancreas, in abdominal trauma, in vesico-ureteric reflux and in transcranial studies. The liver section of the guidelines opens with a rationale for beginning with characterisation of focal lesions rather than their detection, as may seem logical. This points up a fundamental awkwardness of the way USCM work in the liver: the initial arterial phase is particularly useful for differentiating between various focal lesions, while the late (sinusoidal) phase is critical for determining the malignant nature of solid liver lesions. Benign lesions such as haemangiomas and focal nodular hyperplasia have a rich arterial supply and often enhance early in the arterial phase. In haemangiomas, the blood enters the lakes that constitute the abnormality at the periphery of the lesion, giving rise to peripheral nodular enhancement. From here, it percolates towards the centre of the haemangioma, usually fairly slowly, taking up to five minutes to fill completely. At this stage, the lesion disappears as it matches the intensity of the enhanced liver parenchyma, though the process is incomplete in haemangiomas that contain thrombus, usually larger lesions. Thus, delayed scanning is required to confirm that the lesion has disappeared or at least become smaller. FNHs also have an arterial supply via one or several tortuous feeding vessels. However, the flow pattern is distinctive, arriving first at the centre of the lesion and filing it in a centrifugal fashion, often forming a spoke wheel pattern. The enhancement is often intense and very rapid (the “light bulb sign”) and so the early images after arrival of the contrast are critical; the study should be recorded so that these early frames can be reviewed, if necessary in slow motion, to allow the characteristic pattern to be recognised. In the late phase, FNHs disappear as the liver enhancement matches the enhancement in the lesion. In around a quarter of cases, the central scar becomes visible in this phase as a stellate central filling defect. For both lesions, these features carry the same confidence as the equivalent CT or MR haemodynamic findings and do not require further investigation when they are typical, as is the case in around 75% of cases. Atypical cases, which amount to 5 or 10%, require further investigation. Other lesions with diagnostic haemodynamic patterns are focal fatty sparing and change as well as regenerating nodules: they have normal haemodynamics and so behave in exactly the same way as the surrounding liver, disappearing in the late phase. Hepatic adenomas seem to have a variety of patterns, but experience with them is still limited, as it is for other uncommon focal lesions such as granulomas and peliosis.

Contrast-enhanced Ultrasonographic Evaluating Thioacetamide-induced Rabbit Liver Fibrosis

The Clinical Use of Contrast - Enhanced Gray - Scale Ultrasonography in the Diagnosis of Focal Liver Lesions

Quantitative Assessment of Liver Parenchymal Perfusion in Rabbit Liver Fibrosis Model by Contrast-Enhanced Ultrasonography

Quantitative Assessment of Ischemic Liver's Elastic Changes in Rabbits Using Acoustic Radiation Force Impulse (ARFI)

Clinical application of contrast-enhanced ultrasonography in liver fibrosis

Improved differential diagnosis of focal liver disease using SonoVue with nonlinear scanning mode

Assessment of Liver Fibrosis by Variable Flip Angle T-1 Mapping at 3.0T

Quantitative assessment with contrast-enhanced ultrasonography in a rat model of liver fibrosis

Assessment of the Stage of Liver Fibrosis in a Nat Model with Contrast-Enhanced Quantitative Ultrasonography

Study of Contrast-Enhanced Ultrasound in Diagnosis of Liver Lesions

Diffusion-weighted Imaging and Variable Flip Angle T1 Mapping: a Supplement for Image-Guided Biopsy in Follow-Up Analysis of Liver Fibrosis

Practical Value of Contrast-enhanced Ultrasound in Diagnosing Focal Hepatic Lesions

Assessment of Liver Fibrosis Using Pharmacokinetic Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

[Diagnostic Efficacy of an Ultrasound Quantitative Method in a Rat Model of Experimental Liver Fibrosis].

Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin Αvβ3-Targeting Radiotracer.

Imaging of Focal Liver Lesions

Real-time Contrast Ultrasonography of Focal Liver Lesions

Automated Evaluation of Liver Fibrosis in Thioacetamide, Carbon Tetrachloride, and Bile Duct Ligation Rodent Models Using Second-Harmonic Generation/two-Photon Excited Fluorescence Microscopy

- 32S 2-1 9 th US Contrast The Diagnosis of Liver Tumours with Ultrasound Contrast

Preliminary experimental study on evaluation of liver injury by ultrasonic targeting imaging

Hepatic Fibrosis: Evaluation with Semiquantitative Contrast-enhanced CT